• By Dana Sparks

Genetic Evidence That New Therapies Targeting Parkinson’s Disease May Cause Harm

March 14, 2013

NorthShore University HealthSystem and Mayo Clinic researchers have partnered on a study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein — a gene whose function is involved in the development and progression of Parkinson’s disease — may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson’s disease.

Read EMBARGOED news release: NorthshoreMayo_NR

Mayo Clinic neurology experts are presenting research findings on Parkinson’s disease, Alzheimer’s disease, sleep disorders, concussions, multiple sclerosis and more at the American Academy of Neurology annual meeting in San Diego, March 16–23. They also are available to offer expert comment on other research findings.

Please login or become a member to post a comment.